| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/14/2011 | US20110171313 Composition containing ultra-micronized palmitoyl-ethanolamide |
| 07/14/2011 | US20110171312 Modified therapeutic peptides, methods of their preparation and use |
| 07/14/2011 | US20110171311 Stable hydrogel compositions including additives |
| 07/14/2011 | US20110171310 Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use |
| 07/14/2011 | US20110171309 Compositions and Methods for Composite Nanoparticle Hydrogels |
| 07/14/2011 | US20110171308 Ph-sensitive solid pharmaceutical composition for oral preparation and preparation method thereof |
| 07/14/2011 | US20110171307 Methods and products for treatment of diseases |
| 07/14/2011 | US20110171306 Methods and products for treatment of diseases |
| 07/14/2011 | US20110171305 Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system |
| 07/14/2011 | US20110171304 Injectable beta-hairpin peptide hydrogel that kills methicillin-resistant staphylococcus aureus |
| 07/14/2011 | US20110171303 Dosage form containing (s)-pantoprazole as active ingredient |
| 07/14/2011 | US20110171302 Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs |
| 07/14/2011 | US20110171301 F, G, H, I and K Crystal Forms of Imatinib Mesylate |
| 07/14/2011 | US20110171300 Delta 9 tetrahydrocannabinol derivatives |
| 07/14/2011 | US20110171299 Doxycycline metal complex in a solid dosage form |
| 07/14/2011 | US20110171298 Hard capsule composition and method of use |
| 07/14/2011 | US20110171297 Sustained release formulation for venlafaxine hydrochloride |
| 07/14/2011 | US20110171296 Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine |
| 07/14/2011 | US20110171295 Immediate release compositions of acid labile drugs |
| 07/14/2011 | US20110171294 Enzyme composition and application thereof in the treatment of pancreatic insufficiency |
| 07/14/2011 | US20110171293 Hard capsule composition and method of use |
| 07/14/2011 | US20110171292 Peptide compositions and methods of use |
| 07/14/2011 | US20110171291 Pathologically-activated therapeutics |
| 07/14/2011 | US20110171290 Inhibition of angiogenesis and tumor metastasis |
| 07/14/2011 | US20110171289 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 07/14/2011 | US20110171287 Use of Oligonucleotides with Modified Bases as Antiviral Agents |
| 07/14/2011 | US20110171285 Design of Fibrinogen and Fibrinogen Derived Products with Reduced Bacterial Binding by Using Modified Sequences of Fibrinogen Chains |
| 07/14/2011 | US20110171282 Materials Comprising Water-Soluble Polymer Particles and Methods of Making and Using Them |
| 07/14/2011 | US20110171281 Soft capsule composition and method of use |
| 07/14/2011 | US20110171277 Wound dressing having a polyurethane foam layer and a cover layer made of thermoplastic polymer |
| 07/14/2011 | US20110171276 Non-Viral Compositions and Methods for Transfecting Gut Cells In Vivo |
| 07/14/2011 | US20110171275 Gastroretentive drug delivery system, preparation method and use thereof |
| 07/14/2011 | US20110171274 Fesoterodine Substantially Free of Dehydroxy Impurity |
| 07/14/2011 | US20110171273 Stable anti-nausea oral spray formulations and methods |
| 07/14/2011 | US20110171272 Urological medical devices for release of prostatically beneficial therapeutic agents |
| 07/14/2011 | US20110171271 Citrate-Based Dialysate Chemical Formulations |
| 07/14/2011 | US20110171270 Novel solid state forms of laquinimod and its sodium salt |
| 07/14/2011 | US20110171269 Method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs |
| 07/14/2011 | US20110171268 Uricase compositions and methods of use |
| 07/14/2011 | US20110171142 Metformin glycinate salt for blood glucose control |
| 07/14/2011 | US20110171141 Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| 07/14/2011 | US20110171140 Absorption of therapeutic agents across mucosal membranes or the skin |
| 07/14/2011 | US20110171139 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| 07/14/2011 | US20110171138 Substantially pure deferasirox and processes for the preparation thereof |
| 07/14/2011 | DE102010000043A1 Inhalatorsystem für flüchtige Substanzen Inhalatorsystem for volatile substances |
| 07/14/2011 | CA2790197A1 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| 07/14/2011 | CA2786651A1 Functionalised triblock copolymers and compositions containing such polymers |
| 07/14/2011 | CA2786598A1 Topical transdermal dexmedetomidine compositions and methods of use thereof |
| 07/14/2011 | CA2786585A1 Methods and compositions for liquidation of tumors |
| 07/14/2011 | CA2786525A1 Methods and compositions for applying moxifloxacin to the ear |
| 07/14/2011 | CA2786400A1 Biomaterials made from human hair |
| 07/14/2011 | CA2786306A1 Methods and compositions for providing protective immunity in the elderly |
| 07/14/2011 | CA2786233A1 Anti-inflammatory analgesic adhesive patch for external use |
| 07/14/2011 | CA2786026A1 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| 07/14/2011 | CA2785920A1 Solid oral dosage form containing olmesartan medoxomil |
| 07/14/2011 | CA2785754A1 Compositions comprising pigment particles entrapped in collapsed polymeric microspheres, and methods of making the same |
| 07/14/2011 | CA2785595A1 Dry powder fibrin sealant |
| 07/14/2011 | CA2784772A1 Mesalamine suppository |
| 07/14/2011 | CA2784704A1 Temperature-dependent activation of catalytic nucleic acids for controlled active substance release |
| 07/14/2011 | CA2784601A1 Implantable device with intravesical tolerability and methods of treatment |
| 07/14/2011 | CA2784407A1 Abuse-resistant formulations |
| 07/14/2011 | CA2784120A1 Compositions and methods for oral drug delivery |
| 07/14/2011 | CA2783846A1 Antibody formulation |
| 07/14/2011 | CA2782075A1 Nestorone/estradiol transdermal gel |
| 07/14/2011 | CA2781260A1 Oral care compositions for use with an oral light device |
| 07/13/2011 | EP2343370A1 A throbin-like enzyme of agkistrodon acutus |
| 07/13/2011 | EP2343316A1 Ligand binding site of RAGE and uses thereof |
| 07/13/2011 | EP2343088A1 Antimycotic and prebiotic pharmaceutical composition and a method for treating candidal vaginitis |
| 07/13/2011 | EP2343078A1 Light-stabilized pharmaceutical composition |
| 07/13/2011 | EP2343076A1 Pharmaceutical composition for oral administration |
| 07/13/2011 | EP2343072A1 Remedy |
| 07/13/2011 | EP2343071A1 Pharmaceutical dosage forms |
| 07/13/2011 | EP2343067A1 Pharmaceutical composition for the eradication of helicobacter pylori and preparation method thereof |
| 07/13/2011 | EP2343065A1 The pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof |
| 07/13/2011 | EP2343061A1 Use of tall oil pitch extract and compositions which contain it |
| 07/13/2011 | EP2343060A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/13/2011 | EP2343059A1 Oral preparation |
| 07/13/2011 | EP2343058A2 A pharmaceutical formulation containing olanzapine |
| 07/13/2011 | EP2343057A1 Method and composition for administering an NMDA receptor antagonist to a subject |
| 07/13/2011 | EP2343056A1 Producing stable adefovir dipivoxil solid dispersions |
| 07/13/2011 | EP2343055A1 Pharmaceutical compositions of pregabalin |
| 07/13/2011 | EP2343054A1 Pellets and microparticles of pravastatin sodium and a process of making them |
| 07/13/2011 | EP2343053A1 Nanoparticulate posaconazole formulations |
| 07/13/2011 | EP2343052A1 Hydrophilic filtration during manufacture of vaccine adjuvants |
| 07/13/2011 | EP2343051A2 Anti-cancer formulation |
| 07/13/2011 | EP2343048A2 Stabilized and preserved ketotifen ophthalmic compositions |
| 07/13/2011 | EP2343047A2 Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 07/13/2011 | EP2343046A1 Functionalised triblock copolymers and compositions containing such polymers |
| 07/13/2011 | EP2343045A2 Transmucosal drug delivery system |
| 07/13/2011 | EP2343044A1 Cosmetic composition for sensitive skins |
| 07/13/2011 | EP2343038A1 Dermatological compositions comprising a combination of peroxidized lipids and zinc for use amongst others in the treatment of herpes |
| 07/13/2011 | EP2341941A2 Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| 07/13/2011 | EP2341940A1 The stabilisation of proteins |
| 07/13/2011 | EP2341910A1 Immediate release dosage forms of sodium oxybate |
| 07/13/2011 | EP2341901A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion |
| 07/13/2011 | EP2341899A1 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
| 07/13/2011 | EP2341898A2 Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
| 07/13/2011 | EP2341897A2 Nanoparticles for immunotherapy |
| 07/13/2011 | EP2341896A1 Lipid pellets with enhanced taste-masking |
| 07/13/2011 | EP2341895A2 Hyaluronic acid cryogel - compositions, uses, processes for manufacturing |